QSP models join a drug's pharmacokinetics to its pharmacodynamics through the biology of the disease: pathways, cells and feedbacks, down to a clinical endpoint. Each model here was rebuilt from its original publication as an mrgsolve model and runs in your browser; nothing to install. The first load takes about half a minute while R starts up in the page.
The humoral coagulation network with warfarin PK and the vitamin K cycle. Clotting factors fall at their own turnover rates, and the prothrombin time of a simulated plasma sample gives the INR.
Open the appCalcium and phosphate homeostasis joined to osteoblast and osteoclast remodelling. Follows CTx, bone-specific ALP and lumbar-spine BMD through treatment and after stopping.
Open the appEGFR-RAS-RAF-MEK-ERK signalling with feedback, tumour growth and four targeted drugs. Simulates a virtual trial for any combination and compares regimens in the same patients.
Open the appThe 4GI model: glucose, insulin, GLP-1, glucagon and GIP with the feedbacks between them, in healthy volunteers and type 2 diabetes, with a GLP-1 receptor agonist.
Open the appLNP uptake by innate cells, dendritic-cell maturation, helper T cells, B cells in 17 affinity classes and the antibody response to BNT162b2 and mRNA-1273, against trial data. Change dose, interval and boosters.
Open the appTargeted protein degradation: ternary complex formation with cooperativity, catalytic degradation on top of target turnover, and the hook effect. Predicts Dmax, DC50 and DCmax for a series of BTK degraders from their binding constants.
Open the appTrastuzumab emtansine crosses tumour vessels, binds HER2, is internalised and releases its DM1 payload inside the cell. Eleven mouse tumour models give the killing constants; human PK is scaled from monkeys; weekly and front-loaded regimens are compared with every 3 weeks.
Open the appMosunetuzumab tethers T cells to B cells across blood, spleen, lymph nodes and marrow. Compares step-up and full first doses: B-cell killing, T-cell activation and margination, and the IL-6 surge that drives cytokine release syndrome.
Open the appTisagenlecleucel expands thousands-fold, contracts, then persists for years. The population model from the pediatric ALL trials, with its between-patient variability, covariates, and the effect of tocilizumab and steroids on expansion.
Open the appEvery model is a single mrgsolve model file. Run locally with mrgsolve installed, the apps simulate through mrgsolve. In the browser the same file is translated to R and solved with a stiff Rosenbrock solver, and the test suite checks the two engines against each other, and each model against its published results, before every deployment. Source: github.com/Wrlog/QSP. For physiologically based pharmacokinetic (PK-only) models, see the PBPK models.